CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-
Go back to CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-| (NASDAQ: CRVO) | Delayed: 4.24 +0.43 (11.29%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.81 | 52 Week High | $ | |||
| Open | $4.68 | 52 Week Low | $ | |||
| Day High | $7.81 | P/E | N/A | |||
| Day Low | $3.84 | EPS | $ | |||
| Volume | 108,063,827 | |||||
